Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin Effect on Atherosclerotic Plaque Metabolism
NCT03233243Phase 4Completed
- Sponsor
- University of Coimbra
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rosuvastatin in atherosclerosis, sponsored by University of Coimbra. Primary endpoint: Variation in 18F-NaF uptake in coronary, aortic and carotid plaques (tissue to background ratio - TBR) at 6 months. Started Jul 2020; status: completed.
02
Drugs
rosuvastatin
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT03233243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233243.